Evidence map›Paper›PMID 35776711›Full record

Trial reportCirculation. Arrhythmia and electrophysiology2022

Ablation of Refractory Ventricular Tachycardia Using Intramyocardial Needle Delivered Heated Saline-Enhanced Radiofrequency Energy: A First-in-Man Feasibility Trial.

Douglas L Packer, David J Wilber, Suraj Kapa, Katia Dyrda, Isabelle Nault, Ammar M Killu, Arvindh Kanagasundram, Travis Richardson, William Stevenson, Atul Verma and 2 more

2 registry-linked trialsOpen access · bronzeAbstract readClinical Trial
In one paragraph

Trial report in Circulation. Arrhythmia and electrophysiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 16 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 2 pooled it
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02994446 nacompletednot on this map

Saline-Enhanced Radiofrequency (SERF) Catheter Ablation for the Treatment of Ventricular Tachycardia

TypeinterventionalSponsorThermedical, Inc.Ran2016 to 2021Enrolled25ConditionsTachycardia, VentricularArmsSaline-Enhanced Radiofrequency Catheter and Ablation System
NCT03628534 nacompletednot on this map

Saline Enhanced Radiofrequency (SERF) VT Ablation Early Feasibility Study (EFS)

TypeinterventionalSponsorThermedical, Inc.Ran2018 to 2022Enrolled16ConditionsVentricular Tachycardia, Arrythmia, Heart Diseases, Cardiovascular DiseasesArmsSaline Enhanced Radiofrequency (SERF) ablation
3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 32 citations in OpenAlex.

  1. Heterogeneity of outcomes reporting in catheter ablation trials for ventricular tachycardia: a systematic review.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026
    Pooled it
  2. Pooled it
  3. Cryocure-VT: the safety and effectiveness of ultra-low-temperature cryoablation of monomorphic ventricular tachycardia in patients with ischaemic and non-ischaemic cardiomyopathies.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2024
    Trial
  4. Advancements in mapping, cardiac imaging, and ablation techniques for the management of ventricular tachycardias.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2026
    Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Twenty-five years of catheter ablation of ventricular tachycardia: a look back and a look forward.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2023
    Article
  14. Management of Ventricular Arrhythmias in Heart Failure.Current heart failure reports · 2023
    Review
  15. Review
  16. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 2 countries.

Douglas L PackerMayo Clinic, Rochester, MN (D.L.P., S.K., A.M.K.).ORCID 0000-0003-2060-869X
David J WilberLoyola Univ Medical Center, IL, Maywood (D.J.W.).ORCID 0000-0002-5086-8217
Suraj KapaMayo Clinic, Rochester, MN (D.L.P., S.K., A.M.K.).ORCID 0000-0003-2283-4340
Katia DyrdaMontreal Heart Institute, QC (K.D.).ORCID 0000-0002-0171-9311
Isabelle NaultCanada Quebec Heart and Lung Institute, Quebec City, Canada (I.N.).ORCID 0000-0003-2156-4625
Ammar M KilluMayo Clinic, Rochester, MN (D.L.P., S.K., A.M.K.).ORCID 0000-0002-5525-1806
Arvindh KanagasundramVanderbilt University Medical Center, Nashville, TN (A.K., T.R., W.S.).ORCID 0000-0001-8295-1528
Travis RichardsonVanderbilt University Medical Center, Nashville, TN (A.K., T.R., W.S.).ORCID 0000-0002-9772-0308
William StevensonVanderbilt University Medical Center, Nashville, TN (A.K., T.R., W.S.).ORCID 0000-0002-2118-7893
Atul VermaSouthlake Regional Health Centre, Newmarket Ontario, Canada (A.V.).ORCID 0000-0002-1020-9727
Michael CurleyThermedical, Inc, Waltham, MA (M.C.).ORCID 0000-0002-4316-0237
SERF Investigators
Mayo Clinic · USVanderbilt University Medical Center · USLoyola University Medical Center · USLung Institute · USMontreal Heart Institute · CASouthlake Regional Health Center · CAThermedical (United States) · US

Funding

Catheter Ablation versus Antiarrythmic Drug Therapy for Atrial Fibrilllation TriaU01HL089709 · NHLBI · MAYO CLINIC ROCHESTER · PI PACKER, DOUGLAS L · 2009 to 2014
$4.4M
Eliminating Ventricular Tachycardia: Pivotal Clinical Trial using the Durablate® CatheterR44HL169112 · NHLBI · THERMEDICAL, INC. · PI CURLEY, MICHAEL G · 2023 to 2025
$3.0M
Eliminating Ventricular Tachycardia: First in Human Clinical Trial using the Durablate™ CatheterR44HL132746 · NHLBI · THERMEDICAL, INC. · PI CURLEY, MICHAEL G · 2017 to 2018
$2.8M
NHLBI NIH HHS R44 HL132746NHLBI NIH HHS R44 HL169112NHLBI NIH HHS U01 HL089709
6 · The paper itself

Abstract

backgroundAblation of ventricular tachycardia (VT) is limited by the inability to create penetrating lesions to reach intramyocardial origins. Intramural needle ablation using in-catheter, heated saline-enhanced radio frequency (SERF) energy uses convective heating to increase heat transfer and produce deeper, controllable lesions at intramural targets. This first-in-human trial was designed to evaluate the safety and efficacy of SERF needle ablation in patients with refractory VT.

methodsThirty-two subjects from 6 centers underwent needle electrode ablation. Each had recurrent drug-refractory monomorphic VT after implantable cardioverter defibrillator implantation and prior standard ablation. During the SERF study procedure, one or more VTs were induced and mapped. The SERF needle catheter was used to create intramural lesions at targeted VT site(s). Acute procedural success was defined as noninducibility of the clinical VT after the procedure. Patients underwent follow-up at 30 days, and 3 and 6 months, with implantable cardioverter defibrillator interrogation at follow-up to determine VT recurrence.

resultsThese refractory VT patients (91% male, 66±10 years, ejection fraction 35±11%; 56% ischemic, and 44% nonischemic) had a median of 45 device therapies (shock/antitachycardia pacing) for VT in the 3 to 6 months pre-SERF ablation. The study catheter was used to deliver an average of 10±5 lesions per case, with an average of 430±295 seconds of radiofrequency time, 122±65 minute of catheter use time, and a procedural duration of 4.3±1.3 hours. Acute procedural success was 97% for eliminating the clinical VT. At average follow-up of 5 months (n=32), device therapies were reduced by 89%. Complications included 2 periprocedural deaths: an embolic mesenteric infarct and cardiogenic shock, 2 mild strokes, and a pericardial effusion treated with pericardiocentesis (n=1).

conclusionsIntramural heated saline needle ablation showed complete acute and satisfactory mid-term control of difficult VTs failing 1 to 5 prior ablations and drug therapy. Further study is warranted to define safety and longer-term efficacy. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique Identifier: NCT03628534 and NCT02994446.

Indexed as

Catheter AblationTachycardia, VentricularFeasibility StudiesFemaleHot TemperatureHumansMaleTreatment Outcomecatheterheatingpericardial effusionshock, cardiogenictachycardia, ventricular

Identifiers

PMID35776711
PMCPMC9388560
OpenAlexW4283774215

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.